Aeglea Bio Therapeutics (NASDAQ:AGLE) Upgraded to “Hold” by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) from a sell rating to a hold rating in a research note released on Thursday, BidAskClub reports.

A number of other equities analysts have also weighed in on AGLE. ValuEngine upgraded Aeglea Bio Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. HC Wainwright reiterated a buy rating and issued a $20.00 price target on shares of Aeglea Bio Therapeutics in a research report on Monday, June 3rd. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Aeglea Bio Therapeutics has a consensus rating of Buy and an average target price of $14.33.

NASDAQ:AGLE opened at $8.50 on Thursday. The company has a quick ratio of 8.44, a current ratio of 8.44 and a debt-to-equity ratio of 0.05. Aeglea Bio Therapeutics has a 1-year low of $5.99 and a 1-year high of $10.49. The firm has a market capitalization of $256.21 million, a price-to-earnings ratio of -3.99 and a beta of 1.09. The stock has a fifty day simple moving average of $8.06 and a 200 day simple moving average of $7.41.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.07). Equities analysts predict that Aeglea Bio Therapeutics will post -2.28 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter worth about $27,000. BNP Paribas Arbitrage SA acquired a new stake in Aeglea Bio Therapeutics during the 1st quarter worth about $32,000. Bank of Montreal Can boosted its position in Aeglea Bio Therapeutics by 116.5% during the 2nd quarter. Bank of Montreal Can now owns 6,749 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 3,631 shares during the period. Commonwealth Equity Services LLC acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter worth about $68,000. Finally, Susquehanna International Group LLP acquired a new stake in Aeglea Bio Therapeutics during the 2nd quarter worth about $83,000. Hedge funds and other institutional investors own 69.35% of the company’s stock.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

See Also: Diversification

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Paypal  Releases Q4 Earnings Guidance
Paypal Releases Q4 Earnings Guidance
XMCT Price Down 13.4% Over Last Week
XMCT Price Down 13.4% Over Last Week
Apex Price Reaches $0.0033
Apex Price Reaches $0.0033
DAO.Casino  One Day Volume Hits $373.00
DAO.Casino One Day Volume Hits $373.00
Scry.info  Price Tops $0.0079 on Top Exchanges
Scry.info Price Tops $0.0079 on Top Exchanges
Advanced Internet Blocks  24 Hour Trading Volume Tops $25.00
Advanced Internet Blocks 24 Hour Trading Volume Tops $25.00


© 2006-2019 Ticker Report